MentionFox
Home › Executive changes › bioAffinity Technologies, Inc.
Leadership changes · BIAF · SEC Form 8-K, Item 5.02

Leadership changes at bioAffinity Technologies, Inc. (2026)

Before you join, sell to or invest in bioAffinity Technologies, Inc.

MentionFox check on bioAffinity Technologies, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/bioaffinity-technologies

Check bioAffinity Technologies, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about bioAffinity Technologies, Inc.?

Who joined and who left bioAffinity Technologies, Inc. (BIAF)? 1 filing reported on 2026-03-06, each cited to the company's own filing.

As of November 14, 2026, bioAffinity Technologies, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 6, 2026 (Form 8-K, March 6, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies ↓

Sell to companies like bioAffinity Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-03-06

bioAffinity Technologies, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-06. Every row below is cited to the filing it comes from, and this page adds each new change as bioAffinity Technologies, Inc. files it.

Also on the record for bioAffinity Technologies, Inc.

DateRecordFigureOur pageSource
June 18, 2026IPO filing, Form 424B4$0.8 a shareIPO filingsSource
June 16, 2026IPO filing, Form S-1/A—IPO filingsSource
June 12, 2026IPO filing, Form S-1—IPO filingsSource
April 30, 2026IPO filing, Form S-1—IPO filingsSource
October 1, 2025Stake report, Schedule 13G, by Bigger Michael5.79% of the class5%+ stakesSource
September 30, 2025IPO filing, Form 424B4—IPO filingsSource
September 25, 2025IPO filing, Form S-1/A—IPO filingsSource
September 24, 2025IPO filing, Form S-1—IPO filingsSource
September 15, 2025IPO filing, Form S-1/A—IPO filingsSource
August 29, 2025IPO filing, Form S-1—IPO filingsSource
May 7, 2025IPO filing, Form 424B4—IPO filingsSource
May 5, 2025IPO filing, Form S-1/A—IPO filingsSource

Selling to them or working with them? See who runs bioAffinity Technologies, Inc. now and the warning signs.

Watch bioAffinity Technologies, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on bioAffinity Technologies, Inc. and the records around it.

bioAffinity Technologies, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on bioAffinity Technologies, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on bioAffinity Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on bioAffinity Technologies, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 16 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-06Reportednot named in the filing8-K, 2026-03-06
Selling to bioAffinity Technologies, Inc.?

New leaders reset buying decisions — get the Full Report on bioAffinity Technologies, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch bioAffinity Technologies, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at bioAffinity Technologies, Inc., with the record behind each one.

Find candidates like senior executive at bioAffinity Technologies, Inc.

Every change, in the filing's words

Filed 2026-03-06 · 8-K

Reported

On March 5, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the "Board") of bioAffinity Technologies, Inc., a Delaware corporation (the "Company"), of their decisions not to stand for re-election to the Board upon expiration of their current terms, which expire at the Company's 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026 (the "Annual Meeting").

Also stated in this filing

  • Mr. Anderson's and Mr. Joyce's decisions not to stand for re-election at the Annual Meeting did not result from any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

Tools for this story

Each opens in a new tab, filled in for bioAffinity Technologies, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/bioaffinity-technologies
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of bioAffinity Technologies, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/bioaffinity-technologies